The first trial involving claims from plaintiffs that use of Fosamax® (alendronic acid) resulted in osteonecrosis of the jaw (or dead jaw syndrome) is scheduled to begin next week in New York. The author of this article discusses the following:

• Fosamax on trial for the first time
• Does Fosamax cause dead jaw syndrome?
• How widespread is dead jaw syndrome?
• A healthy risk-benefit ratio?